Vintafolide: A Novel Targeted Epithelial Ovarian Cancer Agent
Vintafolide: A Novel Targeted Epithelial Ovarian Cancer Agent
Vintafolide is a folic acid, DAVBLH conjugate that binds with high affinity to the FR, which is overexpressed in the majority of ovarian cancers. In Phase I trial vintafolide demonstrated a favorable AE profile and was well tolerated. In Phase II trial vintafolide in combination with PLD was the first combination to demonstrate a statistically significant increase in PFS in women with platinum-resistant ovarian cancer. Technetium-labeled EC20 was effective in selecting patients with FR-positive tumors most likely to benefit from vintafolide therapy. An ongoing Phase III trial will further asses the efficacy of combination vintafolide and PLD in patients with platinum-resistant ovarian cancer.
Conclusion
Vintafolide is a folic acid, DAVBLH conjugate that binds with high affinity to the FR, which is overexpressed in the majority of ovarian cancers. In Phase I trial vintafolide demonstrated a favorable AE profile and was well tolerated. In Phase II trial vintafolide in combination with PLD was the first combination to demonstrate a statistically significant increase in PFS in women with platinum-resistant ovarian cancer. Technetium-labeled EC20 was effective in selecting patients with FR-positive tumors most likely to benefit from vintafolide therapy. An ongoing Phase III trial will further asses the efficacy of combination vintafolide and PLD in patients with platinum-resistant ovarian cancer.
